XML 21 R8.htm IDEA: XBRL DOCUMENT v3.20.4
STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Cash flows from operating activities:      
Net loss $ (75,617) $ (68,548) $ (27,017)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 158 64 59
Accretion and amortization on investments, net 818 (1,534) (978)
Amortization of debt issuance costs/debt discount 179    
Gain on sales of available for sale securities (19)    
Net gain on exchange and sales of equity investment (148)    
Change in fair value of equity investment, including foreign currency translation (163) 196 604
Stock-based compensation for services by non-employees 85 68 191
Stock-based compensation for employees and directors 6,895 6,079 6,368
Amortization related to 401(k) contributions   9 9
Amortization of right-of use-assets 777 712  
Changes in assets and liabilities:      
Interest and other receivables 80 366 (528)
Prepaid and other current assets (1,286) 121 (752)
Deposit and other assets (206) (964)  
Accounts payable 5,731 199 479
Accrued compensation and benefits 3,388 2,188 (743)
Amount due to Janssen Biotech, Inc. (14,269) 11,659 908
Accrued liabilities 7,397 6,211 391
Operating lease liabilities (452) (655)  
Net cash used in operating activities (66,652) (43,829) (21,009)
Cash flows from investing activities:      
Purchases of property and equipment (401) (413) (16)
Purchases of marketable securities (313,201) (153,467) (188,365)
Proceeds from sales of securities available for sale 7,681    
Proceeds from maturities of marketable securities 200,262 181,280 110,663
Proceeds from sales of equity investment 339    
Net cash (used in) provided by investing activities (105,320) 27,400 (77,718)
Cash flows from financing activities:      
Proceeds from issuances of common stock from equity plans 208 204 6,951
Proceeds from issuance of common stock and warrants in public offering, net of paid issuance costs 140,184    
Proceeds from issuances of common stock from at market offerings, net of paid issuance costs 4,075 19,295 86,017
Proceeds from exercise of warrants 16    
Proceeds from debt financing, net of paid debt issuance costs and debt discounts 23,863    
Net cash provided by financing activities 168,346 19,499 92,968
Net (decrease) increase in cash, cash equivalents and restricted cash (3,626) 3,070 (5,759)
Cash, cash equivalents and restricted cash at the beginning of the period 13,914 10,844 16,603
Cash, cash equivalents and restricted cash at the end of the period $ 10,288 $ 13,914 $ 10,844